David W. Pook

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 01, 2026

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

Journal: Clinical genitourinary cancer

Published: January 16, 2026

WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.

WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.

Journal: European urology oncology

Published: November 19, 2025

WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.

WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.

Journal: European urology oncology

Published: November 19, 2025

Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304).

Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304).

Journal: European urology oncology

Published: November 10, 2025

Correlation of Tumor Absorbed Dose with Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA.

Correlation of Tumor Absorbed Dose with Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA.

Journal: Journal of nuclear medicine technology

Published: June 06, 2025

The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study.

The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study.

Journal: British journal of clinical pharmacology

Published: May 16, 2025

Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).

Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).

Journal: Cancer

Published: March 12, 2025

First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial.

First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial.

Journal: European urology

Published: February 18, 2025

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 23, 2025

Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).

Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).

Journal: Future oncology (London, England)

Published: January 17, 2025

Intravesical gemcitabine and docetaxel vs. re-induction Bacillus Calmette Guerin as first-line salvage therapy for non-muscle invasive bladder cancer.

Intravesical gemcitabine and docetaxel vs. re-induction Bacillus Calmette Guerin as first-line salvage therapy for non-muscle invasive bladder cancer.

Journal: BJUI compass

Published: January 12, 2025

Showing 1-12 of 48

Last Updated: 09/26/2026